DTx Pharma Completes $100M Series B Financing to Advance its FALCON™ Platform and Pipeline of RNA...

DTx Pharma Completes $100M Series B Financing to Advance its FALCON™ Platform and Pipeline of RNA Therapeutics

"Proceeds will enable further platform development and accelerate the path toward clinical development

Matthew Hammond, Ph.D., Principal at RA Capital Management, and Dan Becker, M.D., Ph.D., Partner at Access Biotechnology, will join DTx Pharma's board of directors..."

030221 DTx Pharma Completes $100M Series

.

Download • 68KB